Osteoporosis management in hematologic stem cell transplant recipients: Executive summary

Journal of Bone Oncology

J.J. Body¹  T.J. de Villiers²  D.L. Kendler³  R. Broady⁴  P.R. Ebeling⁵  G. Guglielmi⁶  R. Rizzoli⁷  P. Hadji⁸  M.J. Cannata-Ortiz⁹  D.D. Pierroz^1,10  M.L. Brandi^1,11  A. El Maghraoui^1,12  J. Cannata-Andia^1,13 

[1] CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium;Department of Gynaecology, Faculty of Health Sciences, Stellenbosch University and Mediclinic Panorama, Cape Town, South Africa;Department of Medicine, Division of Endocrinology, University of British Columbia, Vancouver, Canada;Department of Medicine, Division of Hematology, University of British Columbia, Vancouver, Canada;Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Australia;Department of Radiology, University of Foggia, Foggia, Italy;;Division of Bone Diseases, Geneva University Hospitals &Frankfurt Center of Bone Health, Frankfurt/Main, Germany;Haematology Department, Hospital de la Princesa, IIS Princesa, Madrid, Spain;International Osteoporosis Foundation (IOF), Nyon, Switzerland;Mineral and Bone Metabolic Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy;Rheumatology Department, Military Hospital Mohammed V, Mohammed V-Souissi University, Rabat, Morocco;Servicio de Metabolismo Óseo y Mineral, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain;

关键词: Hematopoietic stem cell;    Transplantation;    Bone loss;    Bone marrow;    Fracture;    Bone mineral density;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: Treatment advances have reduced the adverse events associated with hematopoietic stem cell transplant (HSCT) and led to an increased number of transplants performed. HSCT patients are living longer with concerns on long-term outcomes. Bone fragility and fracture are at the forefront for long-term morbidities post-HSCT. Results: In HSCT recipients, evidence has accumulated to support recommendations for more extensive monitoring of bone fragility and more appropriate administration of osteoporosis pharmacotherapies for patients at high risk of bone loss and/or fracture. Conclusion: This executive summary reports and summarizes the main recommendations published previously, including bone assessment, dietary and lifestyle recommendations and osteoporosis medication.

【 授权许可】

Unknown